Who are Maze Therapeutics, Inc.'s main suppliers?

Maze Therapeutics, Inc. (MAZE) key suppliers include: ALLOY-THERAPEUTICS-INC, Dyne Therapeutics, Inc.. View the full supplier network at chainsifter.com/chain/MAZE.

Who are Maze Therapeutics, Inc.'s major customers?

Maze Therapeutics, Inc. (MAZE) key customers include: NEUROCRINE-BIOSCIENCES-INC, SHIONOGI, TRACE-NEUROSCIENCE-INC, Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. and 9 more. View the full customer network at chainsifter.com/chain/MAZE.

What sector is Maze Therapeutics, Inc. in?

Maze Therapeutics, Inc. (MAZE) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Maze Therapeutics, Inc. Supply Chain Data (MAZE): 19 Verified Relationships

2Suppliers

14Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Maze Therapeutics, Inc. (MAZE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

20Total relationships

3Distinct source URLs

10High confidence

0.798Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Maze Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ALLOY-THERAPEUTICS-INC	ALLOY-THERAPEUTICS-INC	90%	In November 2020, together with Alloy Therapeutics, Inc., or Alloy, we formed Broadwing, a spin-out company
DYN	Dyne Therapeutics, Inc.	72%	Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…

Maze Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
NEUROCRINE-BIOSCIENCES-INC	NEUROCRINE-BIOSCIENCES-INC	92%	the Company granted Neurocrine an exclusive worldwide license to a discovery research program targeting ATXN2, or the Neurocrine License Agreement
SHIONOGI	SHIONOGI	92%	the Company granted Shionogi an exclusive, worldwide, sublicensable license to research, develop, manufacture and commercialize MZE001 and certain other small molecule compounds modulating glycogen s…
TRACE-NEUROSCIENCE-INC	TRACE-NEUROSCIENCE-INC	92%	the Company granted an exclusive worldwide license to a discovery research program targeting UNC13A for the treatment of amyotrophic lateral sclerosis, or the Trace License Agreement
NBIX	Neurocrine Biosciences, Inc.	85%	Reciprocal relationship from NBIX graph: Reciprocal relationship from MAZE graph: . Potential sales milestones and royalties on net product sales will be recognized in the same period that the underl…
NBIX	Neurocrine Biosciences, Inc.	85%	. Potential sales milestones and royalties on net product sales will be recognized in the same period that the underlying net product sales occur as they were determined to relate to the license. The…
DYN	Dyne Therapeutics, Inc.	72%	Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
HTGC	Hercules Capital, Inc.	72%	ment of our Maze Compass platform, or our Compass platform, planned preclinical studies, IND filings and clinical trials for future therapeutic candidates. We will also incur substantial additional e…
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from MAZE graph: ment of our Maze Compass platform, or our Compass platform, planned preclinical studies, IND filings and clinical tri…
SGIOF	Shionogi & Co., Ltd.	72%	ecognized over a weighted average period of 1.67 years. 8. License agreements Trace License Agreement In March 2024, the Company entered into an exclusive license agreement with Trace Neuroscience, I…
SGIOF	Shionogi & Co., Ltd.	72%	Reciprocal relationship from SGIOF graph: Reciprocal relationship from MAZE graph: Reciprocal relationship from SGIOF graph: Reciprocal relationship from MAZE graph: ecognized over a weighted average…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from MAZE graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MAZE graph: cal trials for our lead programs …
SNYNF	Sanofi	72%	cal trials for our lead programs may not be predictive of the results of outcomes in subsequent clinical trials. Later-stage clinical trials could differ in significant ways from early-stage clinical…
CO-LTD	CO-LTD	62%	ecognized over a weighted average period of 1.67 years. 8. License agreements Trace License Agreement In March 2024, the Company entered into an exclusive license agreement with Trace Neuroscience, I…
COMPANY-LTD	COMPANY-LTD	62%	Item 1 of this Annual Report on Form 10-K for additional details. In September 2025, we announced positive clinical results from our Phase 1 healthy volunteer study of MZE782. We plan to initiate two…

Maze Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
MAZE-DEBT-16953	Warrants outstanding: 1000	90%	xbrl warrant detail from xbrl 2025-12-31.
MAZE-DEBT-10871	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
MAZE-DEBT	Debt stack $39.0M	90%	Market cache reports total debt of $39.0M.

Maze Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Maze Therapeutics, Inc..

Maze Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
MAZE-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 169 tracked holders.

Maze Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ATOS	Atossa Therapeutics, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
HTGC	Hercules Capital, Inc.	100.00	1	['customer']
BLRX	BioLineRx Ltd.	100.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	1	['customer', 'supplier']
ANRO	Alto Neuroscience, Inc.	100.00	2
IRON	Disc Medicine, Inc.	100.00	2

Maze Therapeutics, Inc. Supply Chain